Safety profile of riluzole(Rilutek~R)in the treatment of amyotrophic lateral sclerosis

摘要

Amyotrophic lateral sclerosis(ALS)is a rapidly fatal degenerative disorder of the motoneurones which was without any effective therapy until 1997. Riluzole(Rilutek~R)has been the first patented drug used in its specific treatment. In order to evaluate the tolerability profile of this molecule, a Pharmacovigilance study was undertaken in the Department of Neurology B at the Montpellier University Hospital. A total of 153 patients were studied and all Observed side-effects were listed in the French bank of Pharmacov- Igilance. Riluzole induced one or more adverse effects in 50.3 per Cent of patients.